Knowledge Graph
Graph explorer
Search resolved entities, walk their edges, and read the sentence behind every one.
Entities25 of 207,987
- large language modeltechnology1,048 mentions
- robotic manipulationmarket834 mentions
- artificial intelligencetechnology739 mentions
- reinforcement learningtechnology492 mentions
- density-functional theorytechnology386 mentions
- Transformertechnology372 mentions
- vision-language-action modeltechnology355 mentions
- agentic AItechnology353 mentions
- Vision-Language Modeltechnology321 mentions
- U.S. Food and Drug Administrationorganization320 mentions
- Microsoftorganization291 mentions
- Googleorganization277 mentions
- NVIDIAorganization265 mentions
- Model Context Protocoltechnology232 mentions
- machine learningtechnology204 mentions
- MarketsandMarketsorganization199 mentions
- Claudeproduct192 mentions
- AI agenttechnology188 mentions
- ChatGPTproduct178 mentions
- Anthropicorganization177 mentions
- integrated sensing and communicationtechnology176 mentions
- Amazon Web Services, Inc.organization174 mentions
- OpenAIorganization172 mentions
- diffusion modeltechnology170 mentions
- IBMorganization163 mentions
Entity
VT-7208
product3 mentionslast seen Nov 5, 2026
Next-generation, CNS-penetrant, once-daily oral BTK inhibitor for immune-mediated diseases.
Relationships 9
- VT-7208applies tochronic spontaneous urticaria treatment99% confidence3 sources
- VT-7208applies tofood allergy treatment99% confidence3 sources
- VT-7208applies torelapsing multiple sclerosis treatment99% confidence3 sources
- Processa Pharmaceuticals, Inc.developsVT-720899% confidence3 sources
- U.S. Food and Drug AdministrationapprovesVT-720897% confidence1 source
- VT-7208depends onBruton's tyrosine kinase inhibition95% confidence1 source
- VT-7208depends onBruton's tyrosine kinase inhibitor94% confidence1 source
- Craig CoburnauthoredVT-720890% confidence1 source
- VT-7208composed ofBruton's tyrosine kinase inhibitor88% confidence1 source
Relationship
VT-7208applies tochronic spontaneous urticaria treatment
99% confidence3 supporting mentions
Either name opens that entity’s relationships.
Sources 3
- filingSEC EDGARNov 5, 2026Processa Pharmaceuticals, Inc. 8-K: Item 8.01: Other Events; Item 9.01: Financial Statements and Exhibits
The FDA has cleared the IND application for our planned Phase 2 clinical trial of VT-7208 in CSU
- filingSEC EDGARNov 4, 2026Processa Pharmaceuticals, Inc. 8-K: Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers; Item 8.01: Other Events; Item 9.01: Financial Statements and Exhibits
planned Phase 2 proof-of-concept programs in chronic spontaneous urticaria (CSU)
- filingSEC EDGAROct 29, 2026Processa Pharmaceuticals, Inc. 8-K: Item 8.01: Other Events; Item 9.01: Financial Statements and Exhibits
FDA clears IND for Phase 2 study of VT-7208 in chronic spontaneous urticaria